Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Untch

Showing results (81-90 of 377) with videos related to

Pageof 38
Sort By:
Breast Care (Basel, Switzerland)|December 14, 2017
Targeted Intraoperative Radiotherapy Tumour Bed Boost during Breast-Conserving Surgery after Neoadjuvant Chemotherapy - a Subgroup Analysis of Hormone Receptor-Positive HER2-Negative Breast CancerHans-Christian Kolberg, György Lövey, Leyla Akpolat-Basci, et al.
Carcinogenesis|October 28, 2005
Association of the CASP10 V410I variant with reduced familial breast cancer risk and interaction with the CASP8 D302H variantBernd Frank, Kari Hemminki, Barbara Wappenschmidt, et al.
Breast Care (Basel, Switzerland)|August 2, 2013
Breast Cancer during Pregnancy: An Interdisciplinary Approach in Our InstitutionCristina Pirvulescu, Christine Mau, Holger Schultz, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 17, 2003
ATP chemosensitivity testing in ovarian and breast cancer: early clinical trialsChristian M Kurbacher, Ottilia M Grecu, Ursula Stier, et al.
Breast Cancer Research and Treatment|April 10, 2013
Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancerVolker R Jacobs, Ronald E Kates, Eva Kantelhardt, et al.
The Journal of Clinical Endocrinology and Metabolism|January 26, 2006
Association of prolactin and its receptor gene regions with familial breast cancerAnnika Vaclavicek, Kari Hemminki, Claus R Bartram, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2006
Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancerPhilipp Kiewe, Stephan Hasmüller, Steffen Kahlert, et al.
Breast Care (Basel, Switzerland)|April 10, 2014
HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast CancerNadia Harbeck, Matthias W Beckmann, Achim Rody, et al.
Carcinogenesis|June 25, 2005
Association of death receptor 4 haplotype 626C-683C with an increased breast cancer riskBernd Frank, Kari Hemminki, Kalai S Shanmugam, et al.
Breast (Edinburgh, Scotland)|March 28, 2025
Systematic literature review and trial-level meta-analysis of aromatase inhibitors vs tamoxifen in patients with HR+/HER2- early breast cancerWolfgang Janni, Michael Untch, Nadia Harbeck, et al.
Pageof 38

Showing results (81-90 of 377) with videos related to

Sort By:
Pageof 38
Breast Care (Basel, Switzerland)|December 14, 2017
Targeted Intraoperative Radiotherapy Tumour Bed Boost during Breast-Conserving Surgery after Neoadjuvant Chemotherapy - a Subgroup Analysis of Hormone Receptor-Positive HER2-Negative Breast CancerHans-Christian Kolberg, György Lövey, Leyla Akpolat-Basci, et al.
Carcinogenesis|October 28, 2005
Association of the CASP10 V410I variant with reduced familial breast cancer risk and interaction with the CASP8 D302H variantBernd Frank, Kari Hemminki, Barbara Wappenschmidt, et al.
Breast Care (Basel, Switzerland)|August 2, 2013
Breast Cancer during Pregnancy: An Interdisciplinary Approach in Our InstitutionCristina Pirvulescu, Christine Mau, Holger Schultz, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 17, 2003
ATP chemosensitivity testing in ovarian and breast cancer: early clinical trialsChristian M Kurbacher, Ottilia M Grecu, Ursula Stier, et al.
Breast Cancer Research and Treatment|April 10, 2013
Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancerVolker R Jacobs, Ronald E Kates, Eva Kantelhardt, et al.
The Journal of Clinical Endocrinology and Metabolism|January 26, 2006
Association of prolactin and its receptor gene regions with familial breast cancerAnnika Vaclavicek, Kari Hemminki, Claus R Bartram, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2006
Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancerPhilipp Kiewe, Stephan Hasmüller, Steffen Kahlert, et al.
Breast Care (Basel, Switzerland)|April 10, 2014
HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast CancerNadia Harbeck, Matthias W Beckmann, Achim Rody, et al.
Carcinogenesis|June 25, 2005
Association of death receptor 4 haplotype 626C-683C with an increased breast cancer riskBernd Frank, Kari Hemminki, Kalai S Shanmugam, et al.
Breast (Edinburgh, Scotland)|March 28, 2025
Systematic literature review and trial-level meta-analysis of aromatase inhibitors vs tamoxifen in patients with HR+/HER2- early breast cancerWolfgang Janni, Michael Untch, Nadia Harbeck, et al.
Pageof 38